Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Immucell Corp changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 30 | 28 | −2 |
| Shares | 1.03M | 1.04M | +7.69K (+0.7%) |
| Value | $5.47M | $5.31M | −$161.6K (−3.0%) |
New holders (2)
Institutions that held Immucell Corp at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Mesirow Financial Investment Management, Inc. | 12,178 | $62.0K | 0.00% |
| Advisor Group Holdings, Inc. | 550 | $2.80K | 0.00% |
Sold out (4)
Institutions that held Immucell Corp at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Perritt Capital Management Inc | 27,026 | $144.3K |
| Citadel Advisors LLC | 15,019 | $77.5K |
| Headinvest, LLC | 3,118 | $16.3K |
| US Bancorp | 600 | $3.20K |